OABI refers to OmniAb, Inc., an advanced biotechnology company that specializes in providing proprietary discovery platforms designed to facilitate the identification and development of novel antibody therapeutics. Founded with a mission to empower drug discovery, the company utilizes its proprietary transgenic animal technologies—such as specialized rodent and avian platforms genetically modified to produce human-sequence antibodies—to generate robust immune responses against complex disease targets. OmniAb operates primarily through a business model focused on partnering with global pharmaceutical companies, biotechnology firms, and research institutions, granting them access to its discovery engines in exchange for upfront fees, developmental milestones, and downstream royalties on commercialized drugs. Headquartered in Emeryville, California, the organization leverages its technological capabilities to accelerate the creation of therapeutic candidates spanning oncology, immunology, and various other critical areas of modern medicine.